Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03633929 · ClinicalTrials.gov registry record

mHealth for Patient Self-Management of Opioid Use Disorder

A clinical trial of Opioid Use Disorder, sponsored by Biomedical Development Corporation.

Completed
Registry status
19
Enrollment target
2
Study locations

NCT03633929: Completed study of Opioid Use Disorder, sponsored by Biomedical Development Corporation.

NCT03633929 is a study of Opioid Use Disorder that has completed, run by Biomedical Development Corporation. The registered enrollment target is 19 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03633929, a study of Opioid Use Disorder, has completed, sponsored by Biomedical Development Corporation.

COMPLETED
Registry status
19 participants
Enrollment target
2
Study locations

Study Summary

Twenty individuals diagnosed with opioid use disorder (OUD) will be recruited to participate in a beta test to demonstrate feasibility of using an online tool to help them better self-manage their recovery.

Primary Outcome

The Systems Usability Scale-Modified, a single-factor, 10-item self-report scale was used to evaluate participants' subjective experience using the software. Systems Usability Scale yields a single number representing a composite measure of the overall usability of the system being studied. Systems Usability Scale scores have a range of 0 to 100, with higher scores representing a better outcome. Systems in early development may expect to have a rating of 30, while more mature systems should rate

Conditions Studied

Interventions

  • OTHER KIOS OUD

Study Locations (2)

Texas

  • Biomedical Development Corporation - San Antonio
  • Community Medical Services - San Antonio

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2020-07-08
Est. Completion 2020-09-30

What the finished NCT03633929 record still lists

NCT03633929 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which KIOS OUD is the first listed.

NCT03633929 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03633929 about?

NCT03633929 is a clinical study titled "mHealth for Patient Self-Management of Opioid Use Disorder". Twenty individuals diagnosed with opioid use disorder (OUD) will be recruited to participate in a beta test to demonstrate feasibility of using an online tool to help them better self-manage their recovery.

What is the current status of trial NCT03633929?

This trial is currently completed. The enrollment target is 19 participants. The study started on 2020-07-08. Estimated completion is 2020-09-30.

What conditions does trial NCT03633929 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT03633929?

The interventions under investigation include: KIOS OUD (OTHER).

Who is sponsoring clinical trial NCT03633929?

This trial is sponsored by Biomedical Development Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03633929 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03633929's enrollment target sits among peer trials

19 237th of 257 higher than 20 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03633929, the US trial registry maintained by the National Library of Medicine. NCT03633929 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.